$BIIB Tale of the Tape


Should You Buy Biogen (BIIB) Ahead of Earnings? – Tale of the Tape

Investors are always looking for stocks that are poised to beat at earnings season and Biogen Inc. ( BIIB) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because BIIB is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for BIIB in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at $4.09 per share for BIIB, compared to a broader Zacks Consensus Estimate of $4.07 per share. This suggests that analysts have very recently bumped up their estimates for BIIB, giving the stock a Zacks Earnings ESP of 0.49% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).


Please enter your comment!
Please enter your name here